Last reviewed · How we verify
Other DPP4-i
DPP4 inhibitors block the enzyme dipeptidyl peptidase-4, which prolongs the action of incretin hormones to increase insulin secretion and lower blood glucose in type 2 diabetes.
DPP4 inhibitors block the enzyme dipeptidyl peptidase-4, which prolongs the action of incretin hormones to increase insulin secretion and lower blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Other DPP4-i |
|---|---|
| Sponsor | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders |
| Drug class | DPP4 inhibitor |
| Target | DPP4 (Dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
DPP4 inhibitors work by inhibiting the degradation of GLP-1 and GIP, incretin hormones that are released in response to nutrient intake. By preventing their breakdown, these drugs enhance glucose-dependent insulin secretion from pancreatic beta cells and suppress glucagon release, resulting in improved glycemic control with a low hypoglycemia risk.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Hypoglycemia
- Gastrointestinal disturbances
Key clinical trials
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: